8MV0.F BioHarvest Sciences Inc.
- Market cap
- EUR 32.0M
- P/E
- -
- P/B
- 1.90x
- ROE
- -64.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 8MV0.F undervalued?
Graham numberThe Graham number of BioHarvest Sciences Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
BioHarvest Sciences Inc. fundamental analysis
No fundamental analysis for BioHarvest Sciences Inc. yet.
BioHarvest Sciences Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About BioHarvest Sciences Inc.
BioHarvest Sciences Inc. operates as a biotechnology company in Israel and the United States. It operates through two segments: Products and CDMO Services. The company develops botanical synthesis platform technology to produce plant cells with higher concentrations of active ingredients. It is involved in the research, development, manufacturing, marketing, and sale of science-based health and wellness nutraceutical solutions that are manufactured and sold as dietary supple…
Full company profileBioHarvest Sciences Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
BioHarvest Sciences Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 2.10M | 5.50M | 12.7M | 25.2M | 34.5M | 34.7M |
| Gross Profit | 670K | 1.22M | 5.63M | 13.9M | 20.5M | 20.2M |
| Operating Income | -8.49M | -10.6M | -9.97M | -6.99M | -5.58M | -8.68M |
| EBITDA | - | -9.13M | -9.76M | -6.92M | -6.71M | -6.42M |
| Net Income | -9.83M | -11.2M | -12.6M | -12.9M | -11.1M | -12.7M |
| EPS | -0.76 | -0.85 | -0.92 | -0.75 | -0.49 | -0.56 |
| Balance Sheet | ||||||
| Total Assets | 10.2M | 9.39M | 15.0M | 25.0M | 47.7M | 44.6M |
| Total Liabilities | 7.35M | 15.3M | 29.9M | 23.7M | 22.2M | 24.8M |
| Shareholders' Equity | 2.86M | -5.93M | -14.9M | 1.33M | 25.4M | 19.8M |
| Cash & Short-term Investments | 4.12M | 1.74M | 5.36M | 2.39M | 23.0M | 15.2M |
| Cash Flow | ||||||
| Operating Cash Flow | -6.79M | -9.24M | -8.52M | -6.68M | -7.23M | -8.34M |
| Capital Expenditure | 1.64M | 1.26M | 1.47M | 2.84M | 2.36M | 2.32M |
| Free Cash Flow | -8.43M | -10.5M | -10.00M | -9.52M | -9.58M | -10.7M |
| Ratios | ||||||
| ROE | -344.2% | - | - | -970.9% | -43.8% | -64.3% |
| ROA | -96.3% | -119.6% | -83.7% | -51.6% | -23.4% | -28.5% |
| Net Profit Margin | -467.5% | -204.4% | -99.1% | -51.3% | -32.3% | -36.6% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
BioHarvest Sciences Inc. dividends
BioHarvest Sciences Inc. has not paid dividends in the last 6 fiscal years.
Last stock split: 1:35 on Jun 3, 2024.
Who owns BioHarvest Sciences Inc.
- Insiders 14.77%
- Institutions 7.60%
- Public & others 77.63%
- Shares outstanding 22.7M
- Free float 19.3M
BioHarvest Sciences Inc. company profile
- Company name
- BioHarvest Sciences Inc.
- Ticker
- 8MV0.F
- ISIN
- CA09076J2074
- Exchange
- Frankfurt Exchange
- Sector
- Consumer Defensive
- Industry
- Packaged Foods
- Employees
- 89
- Fiscal year end
- December
- Address
- 1140-625 Howe Street, Vancouver, BC, Canada, V6C 2T6
- Phone
- 604 689 5722
- Website
- bioharvest.com
About BioHarvest Sciences Inc.
BioHarvest Sciences Inc. operates as a biotechnology company in Israel and the United States. It operates through two segments: Products and CDMO Services. The company develops botanical synthesis platform technology to produce plant cells with higher concentrations of active ingredients. It is involved in the research, development, manufacturing, marketing, and sale of science-based health and wellness nutraceutical solutions that are manufactured and sold as dietary supplements and functional food and beverages, as well as the manufacturing, marketing, and sale of science-based health, pharmaceutical, and cosmeceutical solutions. The company also provides contract development and manufacturing operation services. Further, it offers VINIA, a red grape cell dietary supplement containing the matrix of polyphenols contained in red wine. The company has a strategic collaboration with Tate & Lyle plc for the development of plant-based sweetener molecules. The company is based in Vancouver, Canada.
BioHarvest Sciences Inc. management
8- Dr. Zaki Rakib Ph.D.Co-Founder, CEO, Executive Chairman & President · born 1959
- Dr. Yoheved Hagay Ph.D.Co-Founder & CTO · born 1958
- Ms. Bar DichterChief Financial Officer
- Dr. Ilana Belzer Ph.D.Chief Operating Officer · born 1960
- Mr. David K. RyanVP of Investor Relations & Secretary · born 1967
- Jared TurnerChief Sales Officer
- Dr. Malkit Azachi Ph.D.Vice President of Research & Development
- Ms. Michal Abargel SapirVice President of Regulatory Affairs